Integrative deep-sequencing analysis of cancer samples: Discoveries and clinical challenges

Pharmacogenomics Journal

Volumn 13, Issue 3, 2013, Pages 205-208

  Roukos, D ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Breast cancer; copy number changes; heterogeneity; medulloblastoma; mutations; transcriptome

Indexed keywords

BIOLOGICAL MARKER; TRANSCRIPTION FACTOR RUNX1;

AKT3 GENE; BREAST CANCER; BREAST CARCINOMA; CANCER GENETICS; CANCER MORTALITY; CANCER SURVIVAL; CTDNEP1 GENE; DDX3X GENE; EXOME; GENE DOSAGE; GENE MAPPING; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC ASSOCIATION; HIGH THROUGHPUT SEQUENCING; HUMAN; KDM6A GENE; MAGI3 GENE; MEDULLOBLASTOMA; ONCOGENE; ONCOGENE C MYC; POINT MUTATION; PRIORITY JOURNAL; REVIEW; RUNX1 GENE; SEQUENCE ANALYSIS; TBR1 GENE; TRANSCRIPTOMICS; TRIPLE NEGATIVE BREAST CANCER;

BREAST NEOPLASMS; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MEDULLOBLASTOMA; MUTATION;

EID: 84878251298     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2012.51     Document Type: Review

References (16)

1. Roukos DH, Ku CS. Clinical cancer genome and precision medicine. Ann Surg Oncol 2012; 19: 3646-3650.
2. Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012; 21: 242-252.
3. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486: 400-404.
4. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486: 395-399.
5. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012; 486: 405-409.
6. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486: 353-360.
7. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ et al. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-352.
8. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012; 481: 389-393.
9. Jones DT, Jäger N, Kool M, Zichner T, Hutter B, Sultan M et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012; 488: 100-105.
10. Northcott PA, Shih DJ, Peacock J, Garzia L, Sorana Morrissy A, Zichner T et al. Subgroup-specific structural variation across 1, 000 medulloblastoma genomes. Nature 2012; 488: 49-56.
11. Ideker T, Krogan NJ. Differential network biology. Mol Syst Biol 2012; 8: 565.
12. Roukos DH. Spatiotemporal individual genome code-lifestyle network: revolutionizing personal diagnostics. Expert Rev Mol Diagn 2012; 12: 215-218.
13. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011; 12: 56-68.
14. Roukos DH. Disrupting cancer cells biocircuits with interactome-based drugs: is ''clinical'' innovation realistic? Expert Rev Proteomics 2012; 9: 349-353.
15. Camacho DF, Pienta KJ. Disrupting the networks of cancer. Clin Cancer Res 2012; 18: 2801-2808.
16. Khatri P, Sirota M, Butte AJ. Ten years of pathway analysis: current approaches and outstanding challenges. PLoS Comput Biol 2012; 8: e1002375.